Pregabalin Capsule
Product Images NDC 80425-0177

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 80425-0177). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Pharmacy Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Equation (Equation)

A formula for calculating creatinine clearance (CLcr) using patient age, weight, serum creatinine level, and a gender adjustment factor for females. This formula helps estimate kidney function, with variables including age in years, weight in kilograms, and serum creatinine in mg/dL.*

FDA Label Image

Fig 1 (Fig 1)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin at 200 mg three times a day, 100 mg three times a day, 25 mg three times a day, and placebo, illustrating the relationship of dose and patient improvement.*

FDA Label Image

Fig 10 (Fig 10)

A Kaplan-Meier survival curve graph showing the estimated percentage of subjects without LTR over a period of 180 days. The graph compares two groups: one treated with Pregabalin and one with a placebo, with the Pregabalin group showing a higher percentage of subjects without LTR throughout the study period.*

FDA Label Image

Fig 11 (Fig 11)

A line graph comparing the percent of subjects improved from baseline to Week 12 BOCF for Pregabalin versus Placebo. The x-axis represents percent improvement from 0 to 100, and the y-axis shows the percent of subjects improved from 0 to 100. Two lines are shown: a solid line for Pregabalin and a dotted line for Placebo, illustrating higher improvement rates for Pregabalin across the range.*

FDA Label Image

Fig 12 (Fig 12)

A line chart comparing the percentage of subjects improved from baseline to Week 16 between Pregabalin and placebo groups. The x-axis represents percent improvement from 0 to 100, while the y-axis shows the percent of subjects improved. Pregabalin is represented by a solid line, placebo by a dotted line, with Pregabalin consistently showing higher improvement across the range.*

FDA Label Image

Fig 2 (Fig 2)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin 100 mg three times a day to placebo. The graph displays two lines representing patient improvement rates at varying levels of pain reduction.*

FDA Label Image

Fig 3 (Fig 3)

A line graph showing the percentage of patients improved by different dosages of Pregabalin (75 mg, 150 mg, 300 mg twice a day) compared to placebo. The x-axis represents percent improvement in pain from baseline, ranging from 0 to 100%, and the y-axis shows the percent of patients improved, from 0 to 100%. Higher doses of Pregabalin show greater patient improvement than placebo.*

FDA Label Image

Fig 4 (Fig 4)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, illustrating trends in patient pain improvement over varying improvement percentages.*

FDA Label Image

Fig 5 (Fig 5)

A line graph depicting percent improvement in pain from baseline (x-axis) versus percent of patients improved (y-axis). It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, showing different response rates across varying improvement thresholds.*

FDA Label Image

Fig 6 (Fig 6)

A bar graph illustrating responder rates (%) in two clinical studies labeled Study E1 and Study E3. The horizontal axis shows different treatment groups including placebo and various dosages of an unnamed medication, with quantity of subjects indicated below. The vertical axis represents responder rates from 0 to 60%. Bars are annotated to show statistically significant differences vs. placebo in several groups.*

FDA Label Image

Fig 7 (Fig 7)

A line graph depicting seizure reduction as median percentage change from baseline plotted against pregabalin dose (mg/day). It shows data from four studies (E1 BD, E2 TID, E3 BD, E3 TID) with markers and significant p-values indicating dose-dependent seizure reduction compared to placebo. The x-axis represents dose up to 600 mg/day and the y-axis represents seizure reduction up to 60%.*

FDA Label Image

Fig 9 (Fig 9)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin dosages of 800mg, 450mg, and 300mg daily doses, with Pregabalin 800mg represented by a solid line, 450mg by a dashed line, 300mg by a dash-dot line, and placebo by a dotted line. The y-axis represents percent of patients improved, and the x-axis shows percent improvement in pain from baseline.*

FDA Label Image

Preg #90 (Pregabalin 300mg Cap Qty 90 Ndc 80425 0177)

Label for Pregabalin 300 mg oral capsules, package of 90, labeled by Advanced Rx Pharmacy of Tennessee, LLC, Nashville, TN. The label includes an NDC number 80425-0177 and a lot number with expiration date of 6/30/2023. Storage instructions and a federal law caution about dispensing are also visible.*

FDA Label Image

Structure (Structure)

Chemical structure of Pregabalin. The image depicts the molecular formula with key functional groups, including an amine (NH2) and a carboxyl (CO2H), representing the arrangement of atoms in the Pregabalin molecule.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.